UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/772,090	02/03/2004	Margaret H. Baron	HUIP-P02-060	4153
28120 ROPES & GRA	7590 07/01/200 XY LLP	EXAMINER		
PATENT DOCKETING 39/41			HOWARD, ZACHARY C	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			07/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/772,090	BARON ET AL.
Office Action Summary	Examiner	Art Unit
	ZACHARY C. HOWARD	1646
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perior - Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tird d will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 13. This action is FINAL . 2b) ☐ This action is FINAL . Since this application is in condition for allow closed in accordance with the practice under	ris action is non-final. Fance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 70-75 is/are pending in the application 4a) Of the above claim(s) 73 is/are withdrawn 5) Claim(s) is/are allowed. 6) Claim(s) 70-72 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 70-75 are subject to restriction and/or Application Papers 9) The specification is objected to by the Examination	n from consideration. For election requirement.	
10)☑ The drawing(s) filed on <u>03 February 2004</u> is/a Applicant may not request that any objection to th Replacement drawing sheet(s) including the corre 11)☐ The oath or declaration is objected to by the E	e drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicati iority documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D: 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/772,090 Page 2

Art Unit: 1646

DETAILED ACTION

Status of Application, Amendments and/or Claims

The amendment of 7/3/07 has been entered in full. Claim 74 is amended. Claims 43, 58, 60, 61 and 69 are canceled (claims 1-42, 44-57, 59 and 62-68 were previously canceled). New claim 75 is added.

Claims 70-75 are pending in the instant application.

Claims 73 remains withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species (enhanced vascular growth accompanying ocular neovascularization), there being no allowable generic or linking claim.

In the Office Action mailed 10/9/08, claim 74 was also withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. In the response filed 4/13/09, Applicants traverse this withdrawal and argue that a "hemangioma is a solid, albeit benign, tumor and therefore is drawn to the elected species of solid tumors" (pg 3). Applicants' argument has been fully considered and is found to be persuasive. Claim 74 is rejoined; however, a new election of species is required as set forth below.

Election of Species

A further election of species is required. Applicants' arguments in response to the objections and rejections set forth in the previous Office Action (10/9/08) will be addressed in the next Office Action, following Applicants' election of species.

In the response filed 10/22/07, Applicants elected "enhanced vascular growth accompanying a solid tumor" as the species of "enhanced vascular growth" under consideration. At that time, the claims did not recite any species of solid tumor. Currently, this application contains claims directed to the following patentably distinct species of "solid tumor":

(1) breast cancer; and

Application/Control Number: 10/772,090

Page 3

Art Unit: 1646

(2) hemangioma.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. For example, breast cancer is a malignant form of solid cancer, and a hemangioma is a benign self-involuting form of solid cancer. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of solid tumor for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Currently, claim 70, 71 and 75 are generic with respect to solid tumors; claim 72 is directed to species #1; and claim 74 is directed to species #2.

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are

Art Unit: 1646

added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zachary C. Howard whose telephone number is 571-272-2877. The examiner can normally be reached on M-F 9:30 AM - 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/772,090 Page 5

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Z. C. H./

Examiner, Art Unit 1646

/Bridget E Bunner/
Primary Examiner, Art Unit 1647